ScholarIQanswers from OpenAlex & ORCID
Edward Keystone
ResearcherPublications, citations & collaboration network
Edward Keystone is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Edward Keystone have?
ScholarIQindexed works
Edward Keystone has 571 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Edward Keystone have?
ScholarIQcitation count
Edward Keystone has 37,661 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Edward Keystone?
ScholarIQh-index
Edward Keystone has an h-index of 85 in OpenAlex.
What is the i10-index of Edward Keystone?
ScholarIQi10-index
Edward Keystone has an i10-index of 280 in OpenAlex.
What is the ORCID of Edward Keystone?
ScholarIQorcid
The ORCID for Edward Keystone is on the source record.
What is the OpenAlex record for Edward Keystone?
ScholarIQopenalex
The OpenAlex for Edward Keystone is on the source record.
What are the most-cited papers on Edward Keystone?
ScholarIQmost cited works
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S Smolen, D. Aletaha, J. W. J. Bijlsma, Ferdinand C Breedveld, Dimitrios T. Boumpas, G.-R. Burmester, Bernard Combe, M. Cutolo, Maarten de Wit, M Dougados, Paul Emery, Alan Gibofsky, Juan J. Gómez‐Reino, Boulos Haraoui, J. R. Kalden, Edward Keystone, T. K. Kvien, Iain B. McInnes, E. Martín‐Mola, Carlomaurizio Montecucco, M. Schoels, D. van der Heijde
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
Paul Emery, Edward Keystone, Hans‐Peter Tony, Alain Cantagrel, Ronald van Vollenhoven, Antonio Sánchez, Emma Alecock, J. Lee, Joel M. Kremer
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
David T. Felson, Josef S Smolen, George A. Wells, Bin Zhang, L. van Tuyl, Julia Funovits, Daniel Aletaha, Cornelia F Allaart, Joan M. Bathon, Stefano Bombardieri, Peter Brooks, Andrew Brown, Marco Matucci‐Cerinic, Hyon K. Choi, Bernard Combe, Maarten de Wit, Maxime Dougados, Paul Emery, Daniel E. Furst, Juan J. Gómez‐Reino, Gillian Hawker, Edward Keystone, Dinesh Khanna, John Kirwan, Tore K Kvien, Robert Landewé, Joachim Listing, Kaleb Michaud, E. Martín‐Mola, Pamela Montie, Theodore Pincus, Pamela Richards, Jeffrey N. Siegel, Lee S. Simon, Tuulikki Sokka, Vibeke Strand, Peter Tugwell, Alan Tyndall, Desirée van der Heijde, Suzanne Verstappen, Barbara White, Frederick Wolfe, A. Zink, Maarten Boers
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor, Edward Keystone, Désirée van der Heijde, Michael E. Weinblatt, Liliana Morales, Jaime Reyes Gonzaga, S. S. Yаkushin, Taeko Ishii, Kahaku Emoto, Scott D. Beattie, Vipin Arora, C. Gaich, Terence Rooney, Douglas Schlichting, William L. Macias, Stephanie de Bono, Yoshiya Tanaka